IAG stock edges up as Bernstein lifts target and Morgan Stanley flags cash returns
8 January 2026
1 min read

IAG stock edges up as Bernstein lifts target and Morgan Stanley flags cash returns

London, Jan 8, 2026, 09:29 GMT — Regular session

  • IAG shares rose in London trade, hovering near recent highs after fresh broker calls.
  • Bernstein lifted its price target; Morgan Stanley launched coverage on the U.S.-listed ADRs.
  • Investors are positioning ahead of IAG’s FY-2025 results later this quarter.

Shares in British Airways owner International Consolidated Airlines Group (IAG) rose 0.7% to about 435 pence on Thursday, extending a strong run after Bernstein lifted its target price on the airline group. 1

The move matters now because IAG has become a crowded Europe travel trade, with investors looking for proof that high fares and a tighter aircraft market can keep feeding cash flow. The next big test is IAG’s FY-2025 results, due on Feb. 27. 2

Morgan Stanley, in a note on Tuesday launching coverage of IAG’s U.S.-listed ADRs, pointed to “tight capacity growth” on the North Atlantic and said it sees a clearer path for profits to turn into cash returns for shareholders. The bank’s analysts, led by Axel Stasse, also flagged British Airways’ turnaround and growth in the loyalty business as potential earnings drivers. 3

IAG has been trading near a one-year high this week after a 2.8% jump in the previous session, when it closed at 4.37 pounds and set a new 52-week peak, MarketWatch data showed. 4

Traders also have an eye on levels: the stock has traded between roughly 432 and 437 pence so far on Thursday and remains just shy of its recent 52-week high near 439 pence, according to Investing.com data. 5

But the set-up is not clean. Airlines remain exposed to fuel and currency swings and to any wobble in premium travel demand, and IAG has previously warned of softer conditions in parts of the U.S. market, even when profits beat expectations. 6

Stock Market Today

Home Depot stock price: jobs, inflation and a Feb. 24 earnings test loom

Home Depot stock price: jobs, inflation and a Feb. 24 earnings test loom

7 February 2026
Home Depot shares rose 0.7% to $385.15 Friday, trading between $379.10 and $386.37. Investors await a delayed U.S. jobs report Wednesday and CPI data Friday, both postponed by a brief government shutdown. Home Depot reports fourth-quarter earnings Feb. 24. The Dow closed above 50,000 for the first time.
JPMorgan stock price jumps 4% into weekend as Wall Street braces for a busy data week

JPMorgan stock price jumps 4% into weekend as Wall Street braces for a busy data week

7 February 2026
JPMorgan shares rose 3.95% to $322.40 Friday, outpacing other major banks as U.S. stocks rallied and the Dow closed above 50,000 for the first time. The bank recently completed a $3 billion subordinated notes offering. Investors are watching for delayed U.S. jobs data and inflation figures next week, ahead of JPMorgan’s Feb. 23 company update.
AbbVie stock price: ABBV ends week near $223 after earnings swing — what to watch next

AbbVie stock price: ABBV ends week near $223 after earnings swing — what to watch next

7 February 2026
AbbVie shares rose 2% to $223.43 Friday, capping a volatile week marked by earnings and drug sales scrutiny. Moody’s upgraded AbbVie’s credit rating to A2, citing strong performance in immunology and neuroscience. Investors remain focused on Skyrizi and Rinvoq growth amid rising competition and recent regulatory filings. Trading volume stayed below average, with the stock still 9% off its 52-week high.
SK hynix stock price slips into Monday after S&P upgrade, tech selloff

SK hynix stock price slips into Monday after S&P upgrade, tech selloff

7 February 2026
SK hynix shares closed at 839,000 won, down 0.36% Friday and 8% for the week, as tech stocks retreated across Asia. S&P Global Ratings upgraded the chipmaker to “BBB+” with a positive outlook, citing strong HBM sales. The KOSPI fell 1.4% Friday, ending a six-week winning streak. Traders await Monday’s Seoul open for signs of further tech weakness.
GSK share price slips as hepatitis B drug headline leaves investors wanting the numbers
Previous Story

GSK share price slips as hepatitis B drug headline leaves investors wanting the numbers

Scottish village’s last bar goes on the market as Hillside Hotel near Montrose seeks buyer
Next Story

Scottish village’s last bar goes on the market as Hillside Hotel near Montrose seeks buyer

Go toTop